Cascade Prodrug Inc.

EUGENE, OR · Founded 2009 · Biotech · Private

Hypoxia-activated prodrug therapeutic (CPD100) for wet age-related macular degeneration

Claim this profile

Follows are private to you and power your alerts

Updated · cascadeprodrug.com

Sector
Biotech
Headquarters
EUGENE, OR
Founded
2009
Latest Form D
$200K, Apr 2020
Total capital
$2M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$2M
6 Form D · last Apr 2020
79 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
2 pending

Capital timeline

20122014201620182020FEDERAL ↑EQUITY ↓Cumulative $2M2nd Form D$1.1M3rd Form D$25K4th Form D$350K5th Form D$200K6th Form D$200K
20122014201620182020FEDERAL ↑EQUITY ↓Cumulative $2M2nd Form D$1.1M5th Form D$200K

Latest events

  • Private capital raisedForm D · SEC · 6th filing$200K
  • Private capital raisedForm D · SEC · 5th filing$200K
  • Private capital raisedForm D · SEC · 4th filing$350K
  • Private capital raisedForm D · SEC · 3rd filing$25K
  • Private capital raisedForm D · SEC · 2nd filing$1.1M
  • Private capital raisedForm D · SEC · 1st filing$100K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Allan CochraneExecutive Officer, Director, PromoterNamed in SEC Form D filings
  • August SickDirector, PromoterNamed in SEC Form D filings
  • Christopher G SchellingDirectorNamed in SEC Form D filings
  • Lynnor G StevensonDirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 2
  • PendingCombination Therapy With A Vinca Alkaloid N-oxide And An Immune Checkpoint InhibitorUSPTOApplication 18269526
  • PendingCombination Therapy With A Vinca Alkaloid N-oxide And An Immune Checkpoint InhibitorUSPTOApplication PCTUS2021065059

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .